The FDA granted breakthrough therapy status to AbbVie's experimental direct-acting antiviral regimen, with and without ribavirin, as a therapy for genotype 1 hepatitis C virus. The combo is in late-stage trials in 29 nations.
AbbVie's hepatitis C regimen wins breakthrough designation from FDA
SmartBrief Job Listings for Health Care
Attest Health Care Advisors
|Biotechnology/Pharmaceutical Patent Attorney||
Coats and Bennett PLLC
|Sr. Regulatory Specialist, Biotech Center of Expertise||
BASF, The Chemical Co.
|San Diego, CA|
Meridian Health Plan